Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

2.

Dose intensity versus total dose of chemotherapy: an experimental basis.

Skipper HE.

Important Adv Oncol. 1990:43-64. Review. No abstract available.

PMID:
2182523
3.

Laboratory models: some historical perspective.

Skipper HE.

Cancer Treat Rep. 1986 Jan;70(1):3-7. No abstract available.

PMID:
3943114
4.
5.

Experimental adjuvant chemotherapy: an overview.

Skipper HE.

Recent Results Cancer Res. 1986;103:6-29. No abstract available.

PMID:
3738196
6.

Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy.

Skipper HE, Simpson-Herren L.

Important Adv Oncol. 1985:63-77. No abstract available.

PMID:
3870935
7.

Frank M. Schabel 1918-1983.

Skipper HE, Griswold DP.

Cancer Res. 1984 Feb;44(2):871-2. No abstract available.

8.
9.

Establishment of cross-resistance profiles for new agents.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH.

Cancer Treat Rep. 1983 Oct;67(10):905-22. Review.

PMID:
6354439
10.

Stepwise progress in the treatment of disseminated cancers.

Skipper HE.

Cancer. 1983 May 15;51(10):1773-6.

PMID:
6831345
11.

The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy.

Skipper HE.

Adv Cancer Res. 1983;40:331-63. Review. No abstract available.

PMID:
6362357
12.

Drug control of Ara-C-resistant tumor cells.

Schabel FM Jr, Skipper HE, Trader MW, Brockman RW, Laster WR Jr, Corbett TH, Griswold DP Jr.

Med Pediatr Oncol. 1982;10 Suppl 1:125-48. No abstract available.

PMID:
7162459
13.

Concepts for controlling drug-resistant tumor cells.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr.

Eur J Cancer. 1980;Suppl 1:199-211. No abstract available.

PMID:
6947891
14.

Historic milestones in cancer biology: a few that are important in cancer treatment (revisited).

Skipper HE.

Semin Oncol. 1979 Dec;6(4):506-14. No abstract available.

PMID:
394332
15.

Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.

Skipper HE, Schabel FM Jr, Lloyd HH.

Semin Hematol. 1978 Jul;15(3):207-19. No abstract available.

PMID:
675261
16.

Adjuvant chemotherapy.

Skipper HE.

Cancer. 1978 Mar;41(3):936-40.

PMID:
638979
17.

Thoughts on cancer chemotherapy and combination modality therapy (1974).

Skipper HE.

JAMA. 1974 Nov 18;230(7):1033-5. No abstract available.

PMID:
4608173
18.

Combination chemotherapy for spontaneous AKR lymphoma.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Cheeks JB.

Cancer Chemother Rep 2. 1974 Mar;4(1):53-72. No abstract available.

PMID:
4499910
19.

Combination therapy: some concepts and results.

Skipper HE.

Cancer Chemother Rep 2. 1974 Mar;4(1):137-45. No abstract available.

PMID:
4363649
20.

A quick reference chart on cross resistance between anticancer patients.

Skipper HE, Hutchison DJ, Schabel FM Jr, Schmidt LH, Goldin A, Brockman RW, Venditti JM, Wodinsky I.

Cancer Chemother Rep. 1972 Aug;56(4):493-8. No abstract available.

PMID:
5081592
21.

Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971.

Skipper HE, Schabel FM Jr, Trader MW, Laster WR Jr, Simpson-Herren L, Lloyd HH.

Cancer Chemother Rep. 1972 Jun;56(3):273-87, 289-314. Review.

PMID:
19051488
22.

Spontaneous AK leukemia (lymphoma) as a model for human leukemias and lymphomas.

Skipper HE, Schabel FM Jr.

Cancer Chemother Rep 3. 1972 May;3(1):3-5. No abstract available.

PMID:
4340386
23.

Proceedings: Successes and failures at the preclinical level; where now?

Skipper HE.

Proc Natl Cancer Conf. 1972;7:109-21. No abstract available.

PMID:
4764893
24.

Kinetics of mammary tumor cell growth and implications for therapy.

Skipper HE.

Cancer. 1971 Dec;28(6):1479-99. No abstract available.

PMID:
5127796
25.

Kinetic behavior versus response to chemotherapy.

Skipper HE.

Natl Cancer Inst Monogr. 1971 Dec;34:2-14. Review. No abstract available.

PMID:
4946581
26.

Cancer chemotherapy is many things: G.H.A. Clowes Memorial Lecture.

Skipper HE.

Cancer Res. 1971 Sep;31(9):1173-80. No abstract available.

27.

The "sensitivity" of resting and dividing cells.

Pittillo RF, Schabel FM Jr, Skipper HE.

Klin Oczna. 1971;41(5):137-42. No abstract available.

PMID:
5002845
28.

Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.

Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW.

Cancer Chemother Rep. 1970 Dec;54(6):431-50. No abstract available.

PMID:
5527023
29.

The "sensitivity" of resting and dividing cells.

Pittillo RF, Schabel FM Jr, Skipper HE.

Cancer Chemother Rep. 1970 Jun;54(3):137-42. No abstract available.

PMID:
5003582
30.

Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.

Skipper HE, Perry S.

Cancer Res. 1970 Jun;30(6):1883-97. Review. No abstract available.

31.

Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia.

Skipper HE, Schabel FM Jr, Trader MW, Laster WR Jr.

Cancer Chemother Rep. 1969 Dec;53(6):345-66. No abstract available.

PMID:
5384468
32.

Spontaneous AK leukemia (lymphoma) as a model system.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Simpson-Herren L.

Cancer Chemother Rep. 1969 Dec;53(6):329-44. No abstract available.

PMID:
5384467
33.

Improvement of the model systems.

Skipper HE.

Cancer Res. 1969 Dec;29(12):2329-33. No abstract available.

34.

Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755.

Laster WR Jr, Mayo JG, Simpson-Herren L, Griswold DP Jr, Lloyd HH, Schabel FM Jr, Skipper HE.

Cancer Chemother Rep. 1969 Jun;53(3):169-88. No abstract available.

PMID:
5807479
35.

Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster.

Griswold DP Jr, Schabel FM Jr, Wilcox WS, Simpson-Herren L, Skipper HE.

Cancer Chemother Rep. 1968 Apr;52(3):345-87. No abstract available.

PMID:
5670719
36.
37.

Criteria associated with destruction of leukemia and solid tumor cells in animals.

Skipper HE.

Cancer Res. 1967 Dec;27(12):2636-45. No abstract available.

PMID:
6082300
38.

Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

Skipper HE, Schabel FM Jr, Wilcox WS.

Cancer Chemother Rep. 1967 Jun;51(3):125-65. No abstract available.

PMID:
6043735
39.

Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).

Schabel FM Jr, Laster WR Jr, Skipper HE.

Cancer Chemother Rep. 1967 Jun;51(3):111-24. No abstract available.

PMID:
6043734
40.

Induced mammary carcinoma in the female rat as a drug evaluation system.

Griswold DP, Skipper HE, Laster WR Jr, Wilcox WS, Schabel FM Jr.

Cancer Res. 1966 Oct;26(10):2169-80. No abstract available.

41.
42.

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE.

Cancer Chemother Rep. 1966 May;50(4):219-44. No abstract available.

PMID:
4957125
43.

Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in BDF mice and effects of therapy.

Schabel FM Jr, Skipper HE, Laster WR Jr, Trader MW, Thompson SA.

Cancer Chemother Rep. 1966 Jan-Feb;50(1):55-77. No abstract available.

PMID:
5908738
44.

The effects of chemotherapy on the kinetics of leukemic cell behavior.

Skipper HE.

Cancer Res. 1965 Oct;25(9):1544-50. No abstract available.

45.

Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo.

Schabel FM Jr, Skipper HE, Trader MW, Wilcox WS.

Cancer Chemother Rep. 1965 Oct;48:17-30. No abstract available.

PMID:
5834735
46.

Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites.

Skipper HE, Schabel FM Jr, Wilcox WS, Laster WR Jr, Trader MW, Thompson SA.

Cancer Chemother Rep. 1965 Aug;47:41-64. No abstract available.

PMID:
5829427
47.

Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors.

Wilcox WS, Griswold DP, Laster WR Jr, Schabel FM Jr, Skipper HE.

Cancer Chemother Rep. 1965 Aug;47:27-39. No abstract available.

PMID:
5829426
48.

Experimental evaluation of potential anticancer agents. XVI. Basic study of effects of certain anticancer agents on kinetic behavior of model bacterial cell populations.

Pittillo RF, Schabel FM Jr, Wilcox WS, Skipper HE.

Cancer Chemother Rep. 1965 Aug;47:1-26. No abstract available.

PMID:
5829425
49.

Indirect inhibition of protein synthesis.

Dixon GJ, Rightsel WA, Skipper HE.

Ann N Y Acad Sci. 1965 Jul 30;130(1):249-58. No abstract available.

PMID:
4285573
50.

EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA.

SKIPPER HE, SCHABEL FM Jr, WILCOX WS.

Cancer Chemother Rep. 1965 Apr;45:5-28. No abstract available.

PMID:
14321918

Supplemental Content

Loading ...
Support Center